Pfizer In Clinical Development Deal With Novartis To Advance Treatment Of NASH

Shutterstock photo

(RTTNews.com) - Pfizer Inc. (PFE) said that it reached a non-exclusive clinical development agreement with Novartis ( NVS ) to investigate one or more combination therapies for the treatment of non-alcoholic steatohepatitis or NASH. The financial details of this transaction are not disclosed.

The companies will conduct both non-clinical and Phase 1 clinical studies of Pfizer's investigational therapies, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, currently in Phase 2), a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, Phase 1) and a Ketohexokinase (KHK) Inhibitor (PF-06835919, Phase 2), together with Novartis's tropifexor, a non-bile acid, Farnesoid X receptor (FXR) agonist.

Pfizer said it is building a robust NASH program, which was entirely developed in-house and targets NASH through multiple, diverse pathways of the disease. The collaboration with Novartis helps Pfizer to explore combination approaches at an early stage.

Read the original article on RTTNews (http://www.rttnews.com/2948341/pfizer-in-clinical-development-deal-with-novartis-to-advance-treatment-of-nash.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: World Markets , Stocks , Economy , Commodities
Referenced Symbols: NVS ,

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?